Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure

MeSH terms

• Aged
• Antineoplastic Agents / pharmacokinetics
• Antineoplastic Agents / therapeutic use
• Female
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
• Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
• Leukemia, Lymphocytic, Chronic, B-Cell* / mortality
• Lymphoma, Follicular* / diagnosis
• Lymphoma, Follicular* / drug therapy
• Lymphoma, Follicular* / mortality
• Male
• Middle Aged
• Prognosis
• Purines* / administration & dosage
• Purines* / pharmacokinetics
• Purines* / therapeutic use
• Quinazolinones* / administration & dosage
• Quinazolinones* / pharmacokinetics
• Quinazolinones* / therapeutic use
• Treatment Outcome